Results 181 to 190 of about 110,732 (262)

Understanding Hepatic Encephalopathy: Patient Knowledge, Adherence, and Barriers to Care in Cirrhosis. [PDF]

Cureus
Albusta N, Ali A, Alrahma H.
europepmc   +1 more source

Association of Semaglutide Treatment With Liver Cirrhosis and Hepatocellular Carcinoma in Type 2 Diabetes: A Population‐Based Cohort Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction–associated steatotic liver disease is common among individuals with type 2 diabetes mellitus and substantially increases the risk of liver cirrhosis and hepatocellular carcinoma. Effective therapies that improve metabolic control while preventing advanced liver outcomes are limited.
Assaf Issachar, Talish Razi, Ilya Borochov, Hadar Duskin Bitan, Ronen Arbel   +4 more
wiley   +1 more source

A simple score of sarcopenic obesity predicts all-cause mortality in patients with cirrhosis. [PDF]

Front Med (Lausanne)
Yang Y, Wei T, Yang S, Fei R, Tie C, Han R, Ma D, Jin Q, Wang J, Wang Z, Huang R.   +10 more
europepmc   +1 more source

Serum IGF‐1 and the Risk of Cardio‐Kidney Outcomes in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Metabolic dysfunction‐associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin‐like growth factor 1 (IGF‐1) regulates metabolic and vascular function, but its role in long‐term cardio‐kidney outcomes (CKO) in MASLD remains unclear.
Yongin Cho, Hye‐Sun Park, Tae Seop Lim, Jong Ho Jhee, Jong Hyun Jhee   +4 more
wiley   +1 more source

Association between PNPLA3 rs738409 and susceptibility to etiology-specific liver cirrhosis: a systematic review and meta-analysis. [PDF]

BMC Med Genomics
Yang S, Cheng A.
europepmc   +1 more source

High Prevalence of Metabolic Dysfunction–Associated Steatohepatitis With Significant Fibrosis in Primary Care and Endocrinology Clinics

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Metabolic dysfunction‐associated steatohepatitis (MASH) is a leading cause of cirrhosis. NIS2+ is a recently approved serum‐based test combining two biomarkers (miR‐34a‐5p and YKL‐40) to identify at‐risk MASH (i.e., MASH and significant fibrosis). Objective To assess the prevalence of at‐risk MASH by NIS2+ in individuals from primary care
Srilaxmi Kalavalapalli, Eddison Godinez Leiva, Andrea Ortiz Rocha, Anu Sharma, Diana Barb, Nathaly Cuervo‐Pardo, Kelly Y. Chun, Toni R. Prezant, Margery A. Connelly, Jens T. Rosenberg, Joseph R. Grajo, Fernando Bril, Kenneth Cusi   +12 more
wiley   +1 more source

Association of high risk of liver fibrosis in patients with serious outcomes of adverse drug reactions. [PDF]

Eur J Clin Pharmacol
Henze J, Dormann H, Schneider CV, Meeßen C, Knüppel-Ruppert A, Kriegisch-Stumpf A, Schwab M, Stingl JC, Just KS.   +8 more
europepmc   +1 more source

Association Between SGLT2 Inhibitors and DPP‐4 Inhibitors Use and Risk of Acute Pancreatitis: Findings From Nationwide Case‐Based Analyses

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims The Korean national health insurance claims database was utilised to investigate the association between sodium–glucose cotransporter 2 inhibitors (SGLT2i) or dipeptidyl peptidase‐4 inhibitors (DPP‐4i) and the risk of acute pancreatitis (AP). Materials and Methods Patients with type 2 diabetes mellitus prescribed DPP‐4i or SGLT2i at least
Ye‐Jee Kim, Yun Kyung Cho, Mi‐Sook Kim, Joongyub Lee, Seonghae Kim, Bo Ram Yang   +5 more
wiley   +1 more source

Irony of Iron Overload: Hereditary Hemochromatosis Complicated by Alcoholic Hepatitis, Gastrointestinal Bleeding, and Intramuscular Hematoma. [PDF]

Cureus
Del Mundo HJF, Espiritu AJ, Ong BE, Manansala H, Bhanderi H.   +4 more
europepmc   +1 more source

ADAM17 and its proteolytic targets in disease pathogenesis

The FEBS Journal, EarlyView.
ADAM17 as a multifunctional sheddase with contrasting roles across inflammatory, metabolic, cardiovascular, and neoplastic diseases. Through regulated activation by iRhom, iTAP/FRMD8, and tetraspanins, ADAM17 cleaves diverse membrane ligands and receptors, thereby promoting inflammation, fibrosis, obesity, insulin resistance, and tumor progression ...
Abdulbasit Amin, Marina Badenes
wiley   +1 more source